Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has announced it will report its fourth quarter 2024 financial results after U.S. market close on Thursday, February 27, 2025. The company will host a conference call and webcast, which will be available on the 'Investors' section of Xenon's website with a replay option following the event.
The company is advancing an ion channel product portfolio focused on epilepsy and depression. Their lead candidate, azetukalner, is a novel Kv7 potassium channel opener currently in late-stage clinical development for multiple indications.
Xenon Pharmaceuticals (Nasdaq: XENE), un'azienda biofarmaceutica focalizzata sulle neuroscienze, ha annunciato che riporterà i suoi risultati finanziari del quarto trimestre 2024 dopo la chiusura del mercato statunitense giovedì 27 febbraio 2025. L'azienda ospiterà una conferenza telefonica e un webcast, che saranno disponibili nella sezione 'Investitori' del sito web di Xenon con un'opzione di replay dopo l'evento.
L'azienda sta sviluppando un portafoglio di prodotti per i canali ionici focalizzato su epilessia e depressione. Il loro candidato principale, azetukalner, è un nuovo apritore del canale di potassio Kv7 attualmente in fase di sviluppo clinico avanzato per molteplici indicazioni.
Xenon Pharmaceuticals (Nasdaq: XENE), una empresa biofarmacéutica centrada en neurociencias, ha anunciado que informará sobre sus resultados financieros del cuarto trimestre de 2024 después del cierre del mercado estadounidense el jueves 27 de febrero de 2025. La empresa llevará a cabo una llamada de conferencia y un webcast, que estarán disponibles en la sección 'Inversores' del sitio web de Xenon con una opción de repetición después del evento.
La empresa está avanzando en un portafolio de productos de canales iónicos centrados en la epilepsia y la depresión. Su candidato principal, azetukalner, es un nuevo abridor del canal de potasio Kv7 que actualmente se encuentra en desarrollo clínico avanzado para múltiples indicaciones.
제논 제약 (Nasdaq: XENE)는 신경과학에 중점을 둔 생명공학 회사로, 2025년 2월 27일 목요일 미국 시장 마감 후 2024년 4분기 재무 결과를 발표할 것이라고 발표했습니다. 이 회사는 '투자자' 섹션의 제논 웹사이트에서 이벤트 후 재생 옵션과 함께 사용할 수 있는 컨퍼런스 콜 및 웹캐스트를 주최할 예정입니다.
회사는 간질 및 우울증에 중점을 둔 이온 채널 제품 포트폴리오를 발전시키고 있습니다. 그들의 주요 후보 아제투칼너는 현재 여러 적응증에 대해 후기 단계의 임상 개발 중인 새로운 Kv7 칼륨 채널 개방제입니다.
Xenon Pharmaceuticals (Nasdaq: XENE), une entreprise biopharmaceutique axée sur les neurosciences, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre 2024 après la fermeture du marché américain le jeudi 27 février 2025. L'entreprise organisera une conférence téléphonique et un webinaire, qui seront disponibles dans la section 'Investisseurs' du site Web de Xenon, avec une option de rediffusion après l'événement.
L'entreprise fait progresser un portefeuille de produits de canaux ioniques axé sur l'épilepsie et la dépression. Leur candidat principal, azetukalner, est un nouvel ouvreur de canal potassique Kv7 actuellement en développement clinique avancé pour plusieurs indications.
Xenon Pharmaceuticals (Nasdaq: XENE), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Neurowissenschaften, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal 2024 nach Börsenschluss in den USA am Donnerstag, den 27. Februar 2025, bekannt geben wird. Das Unternehmen wird eine Telefonkonferenz und einen Webcast veranstalten, die in der Rubrik 'Investoren' auf der Website von Xenon verfügbar sein werden, mit einer Wiederholungsoption nach der Veranstaltung.
Das Unternehmen entwickelt ein Produktportfolio für Ionenkanäle, das sich auf Epilepsie und Depression konzentriert. Ihr Hauptkandidat, azetukalner, ist ein neuartiger Kv7-Kaliumkanalöffner, der sich derzeit in der späten klinischen Entwicklung für mehrere Indikationen befindet.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025.
Conference Call/Webcast Information:
| Date: | Thursday, February 27, 2025 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Webcast: | Pre-register here |
| Dial-In: | (800) 715-9871 toll-free or (646) 307-1963 for international callers |
| Conference ID: | 8120798 |
A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
When will Xenon Pharmaceuticals (XENE) release Q4 2024 earnings?
What is Xenon's (XENE) lead drug candidate in development?
What therapeutic areas does XENE focus on?
Where can investors access XENE's Q4 2024 earnings webcast?
